Back to Stocks
Rank #1913ERAS
Erasca, Inc.
$12.39
-2.13% (Daily)
Market Cap
$3.84B
Revenue
$N/A
Rank by MCap
#1913
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jonathan E. Lim M.D.
Headquarters
San Diego, CA
Employees
103
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ...
Erasca, Inc. Price Chart
Loading chart…